Faculty Profiles - FUJIWARA Toshiyoshi

MISC - FUJIWARA Toshiyoshi

Division display 381 - 400 of about 922 ／ All the affair displays >>

Eradication of osteosarcoma by fluorescence-guided surgery with tumor labeling by a killer-reporter adenovirus

Yano S, Miwa S, Kishimoto H, Urata Y, Tazawa H, Kagawa S, Bouvet M, Fujiwara T, Hoffman RM

J Orthop Res doi: 10.1002/jor.23073. [Epub ahead of print] 2015

Strategic approach to concurrent aberrant left gastric vein and aberrant left hepatic artery in laparoscopic distal gastrectomy for early gastric cancer: A case report

Kuwada K, Kuroda S, Kikuchi S, Hori N, Kubota T, Nishizaki M, Kagawa S, Fujiwara T

Asian J Endosc Surg 8 ( 4 ) 454 - 456 2015

6．血液凝固と線溶現象：b）血栓症の予防，診断および治療

黒田新士, 藤原俊義

外科 77 ( 12 ) 1385 - 1390 2015

Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Iwamoto T, Kelly C, Mizoo T, Nogami T, Motoki T, Shien T, Taira N, Hayashi N, Niikura N, Fujiwara T, Doihara H, Matsuoka J

Clin Breast Cancer doi: 10.1016/j.clbc.2015.10.004. 2015

Serum Oxidative/anti-oxidative Stress Balance Is Dysregulated in Potentially Pulmonary Hypertensive Patients with Liver Cirrhosis: A Case Control Study

Masako Terao, Akinobu Takaki, Takayuki Maruyama, Hiroki Oe, Tetsuya Yasunaka, Naofumi Tamaki, Kazufumi Nakamura, Takaaki Tomofuji, Takahito Yagi, Hiroshi Sadamori, Yuzo Umeda, Susumu Shinoura, Ryuichi Yoshida, Kazuhiro Nouso, Daisuke Ekuni, Kazuko Koike, Fusao Ikeda, Hidenori Shiraha, Manabu Morita, Hiroshi Ito, Toshiyoshi Fujiwara, Kazuhide Yamamoto

INTERNAL MEDICINE 54 ( 22 ) 2815 - 2826 2015

Language：English Publisher：JAPAN SOC INTERNAL MEDICINE

Objective Hepatopulmonary syndrome (HPS) is characterized by vascular dilatation and hyperdynamic circulation, while portopulmonary hypertension (POPH) is characterized by vasoconstriction with fibrous obliteration of the vascular bed. Vasoactive molecules such as nitric oxide (NO) are candidate factors for cirrhotic complications associated with these diseases. However, oxidative stress balance is not well characterized in HPS and POPH. The present objective is to investigate the oxidative stress and anti-oxidative stress balance and NO pathway balance in patients with potential HPS and POPH.
Methods We recruited patients with decompensated cirrhosis (n = 69) admitted to our hospital as liver transplantation candidates. Patients exhibiting partial pressure of oxygen lower than 80 mmHg and alveolararterial oxygen gradient (AaDO(2)) >= 15 mmHg were categorized as potentially having HPS (23 of 69 patients). Patients exhibiting a tricuspid regurgitation pressure gradient >= 25 mmHg were categorized as potentially having POPH (29 of 61 patients). Serum reactive oxygen metabolites were measured and anti-oxidative OXY-adsorbent test (OXY) were performed, and the balance of these tests was defined as the oxidative index. The correlation between these values and the clinical characteristics of the patients were assessed in a cross-sectional study.
Results Potential HPS patients exhibited no correlation with oxidative stress markers. Potential POPH patients exhibited lower OXY (p = 0.037) and higher oxidative index values (p = 0.001). Additionally, the vascular NO synthase enzyme inhibiting protein, asymmetric dimethylarginine, was higher in potential POPH patients (p = 0.049). The potential POPH patients exhibited elevated AaDO(2), suggesting the presence of pulmonary shunting.
Conclusion Potential POPH patients exhibited elevated oxidative stress with decreased anti-oxidative function accompanied by inhibited NO production. Anti-oxidants represent a candidate treatment for potential POPH patients.

DOI： 10.2169/internalmedicine.54.4889

Web of Science

researchmap

食道癌におけるFAP(fibroblast activation protein)陽性癌関連線維芽細胞の発現と癌転移の関係

賀島肇, 野間和広, 加藤卓也, 勝部亮一, 二宮卓之, 大原利章, 田澤大, 白川靖博, 香川俊輔, 藤原俊義

日本消化器癌発生学会総会プログラム・抄録集 26th 2015

鉄制御を用いた新しい癌の浸潤・転移抑制治療法の開発

大原利章, 大原利章, 二宮卓之, 野間和広, 賀島肇, 加藤卓也, 勝部亮一, 白川靖博, 藤原俊義

日本消化器癌発生学会総会プログラム・抄録集 26th 2015

癌関連線維芽細胞を標的とした新規食道癌治療法の開発

勝部亮一, 野間和広, 賀島肇, 加藤卓也, 二宮卓之, 大原利章, 田澤大, 白川靖博, 香川俊輔, 小林久隆, 藤原俊義

日本消化器癌発生学会総会プログラム・抄録集 26th 2015

悪性腫瘍のウイルス療法:遺伝子改変ウイルス製剤の開発動向

藤原俊義

BIO INDUSTRY ( 32 ) 34 - 40 2015

ERASと周術期チーム医療

白川靖博, 加藤卓也, 竹原清人, 前田直見, 田辺俊介, 櫻間教文, 野間和広, 足羽孝子, 佐藤健治, 森松博史, 藤原俊義

臨床雑誌外科 77 ( 2 ) 142 - 146 2015

大腸癌早期発見のためのエピジェネティックバイオマーカーの開発

永坂岳司, 藤原俊義

G. I. Research 23 ( 1 ) 38 - 45 2015

Language：Japanese Publisher：(株)先端医学社

癌抑制遺伝子プロモーター領域のCpG island(CGI)に認められるメチル化異常は、当初、癌細胞だけに認められると考えられていたが、正常細胞にも頻度は少ないが認められることが報告されている。そのような癌特異的(と考えられた)DNAメチル化異常を大腸癌早期発見のためのエピジェネティックバイオマーカーに設定した場合、偽陽性率を上昇させることが示唆される。しかし、これらの現象は、注意深く検証していけば、大腸癌の進行度を推測する強力なマーカーに成りうる場合もある。本稿では、大腸癌スクリーニングの現状を概説し、便潜血反応検査(FOBT)を含めて、便から遺伝子変異を検出する方法の歴史的経過を概説したのちに、メチル化DNA検出による大腸癌スクリーニングの可能性について考察する。(著者抄録)

researchmap

MicroRNA as a molecular target for gastrointestinal cancers

Tazawa H, Nagasaka T, Kagawa S, Fujiwara T

Transl Gastrointest Cancer 4 ( 3 ) 219 - 235 2015

消化器がん治療の最前線低侵襲治療と個別化医療

藤原俊義

山口県医学会誌 ( 49 ) 82 - 91 2015

放射線併用ウイルス療法による食道癌治療

藤原俊義

Isotope News ( 740 ) 2 - 6 2015

食道胃接合部手術に対する胸腔内観音開き法再建の検討

加藤卓也, 野間和広, 竹原清人, 前田直見, 田邊俊介, 櫻間教文, 西崎正彦, 香川俊輔, 白川靖博, 藤原俊義

日本消化器外科学会雑誌(Web) 48 ( Supplement1 ) 2015

消化器外科腹部領域のSSIに対する引き寄せと圧着を意識した局所陰圧閉鎖療法の実際

浪花崇一, 近藤喜太, 野間和広, 藤原俊義

日本創傷治癒学会プログラム・抄録集 45th 2015

Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy

Shuya Yano, Yong Zhang, Ming Zhao, Yukihiko Hiroshima, Shinji Miwa, Fuminari Uehara, Hiroyuki Kishimoto, Hiroshi Tazawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman

CELL CYCLE 13 ( 24 ) 3958 - 3963 2014.12

Language：English Publisher：LANDES BIOSCIENCE

Quiescent cancer cells are resistant to cytotoxic agents which target only proliferating cancer cells. Time-lapse imaging demonstrated that tumor-targeting Salmonella typhimurium A1-R (A1-R) decoyed cancer cells in monolayer culture and in tumor spheres to cycle from G(0)/G(1) to S/G(2)/M, as demonstrated by fluorescence ubiquitination-based cell cycle indicator (FUCCI) imaging. A1-R infection of FUCCI-expressing subcutaneous tumors growing in nude mice also decoyed quiescent cancer cells, which were the majority of the cells in the tumors, to cycle from G(0)/G(1) to S/G(2)/M, thereby making them sensitive to cytotoxic agents. The combination of A1-R and cisplatinum or paclitaxel reduced tumor size compared with A1-R monotherapy or cisplatinum or paclitaxel alone. The results of this study demonstrate that A1-R can decoy quiescent cancer cells to cycle to S/G(2)/M and sensitize them to cytotoxic chemotherapy. These results suggest a new paradigm of bacterial-decoy chemotherapy of cancer.

DOI： 10.4161/15384101.2014.964115

Web of Science

researchmap

Establishment of a Non-Invasive Semi-Quantitative Bioluminescent Imaging Method for Monitoring of an Orthotopic Esophageal Cancer Mouse Model

Shinji Kuroda, Tetsushi Kubota, Katsuyuki Aoyama, Satoru Kikuchi, Hiroshi Tazawa, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

PLOS ONE 9 ( 12 ) e114562 2014.12

Language：English Publisher：PUBLIC LIBRARY SCIENCE

Orthotopic models of various types of tumors are widely used in anti-tumor therapeutic experiments in preclinical studies. However, there are few ways to appropriately monitor therapeutic effect in orthotopic tumor models, especially for tumors invisible from the outside. In this study we aimed to establish a non-invasive semi-quantitative bioluminescent imaging method of monitoring an orthotopic esophageal cancer mouse model. We confirmed that the TE8 esophageal cancer cell line implanted orthotopically into the abdominal esophagus of nu/nu mice (n=5) developed not only a main tumor at the implanted site, but also local lymph node metastases and peritoneal disseminations within 6 weeks after inoculation. We established a TE8 cell line that stably expressed the firefly luciferase gene (TE8-Luc). We showed that TE8-Luc cells implanted subcutaneously into nu/nu mice (n=5) grew over time until 5 weeks after inoculation. Tumor volume was strongly correlated with luminescent intensity emitted from the tumor, which was quantified using the IVIS imaging system. We then showed that TE8-Luc cells implanted orthotopically into the mouse abdominal esophagus (n=8) also formed a tumor and that the luminescent intensity of such a tumor, as detected by IVIS, increased over time until 7 weeks after inoculation and was therefore likely to reflect tumor progression. We therefore propose that this orthotopic esophageal cancer model, monitored using the non-invasive semi-quantitative IVIS imaging system, will be useful for in vivo therapeutic experiments against esophageal cancer. This experimental setting is expected to contribute to the development of novel therapeutic technologies for esophageal cancer in preclinical studies.

DOI： 10.1371/journal.pone.0114562

Web of Science

researchmap

Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients

Shunsuke Kagawa, Kunitoshi Shigeyasu, Michihiro Ishida, Megumi Watanabe, Hiroshi Tazawa, Takeshi Nagasaka, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

WORLD JOURNAL OF GASTROENTEROLOGY 20 ( 47 ) 17796 - 17803 2014.12

Language：English Publishing type：Book review, literature introduction, etc. Publisher：BAISHIDENG PUBLISHING GROUP INC

To apply an individualized oncological approach to gastric cancer patients, the accurate diagnosis of disease entities is required. Peritoneal metastasis is the most frequent mode of metastasis in gastric cancer, and the tumor-node-metastasis classification includes cytological detection of intraperitoneal cancer cells as part of the staging process, denoting metastatic disease. The accuracy of cytological diagnosis leaves room for improvement; therefore, highly sensitive molecular diagnostics, such as an enzyme immunoassay, reverse transcription polymerase chain reaction, and virus-guided imaging, have been developed to detect minute cancer cells in the peritoneal cavity. Molecular targeting therapy has also been spun off from basic research in the past decade. Although conventional cytology is still the mainstay, novel approaches could serve as practical complementary diagnostics to cytology in near future. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

DOI： 10.3748/wjg.v20.i47.17796

Web of Science

researchmap

Risk Factors of Morbidity and Predictors of Long-term Survival after Hepatopancreatoduodenectomy for Biliary Cancer

Masashi Utsumi, Hiroshi Sadamori, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Kosei Takagi, Toshiyoshi Fujiwara, Takahito Yagi

HEPATO-GASTROENTEROLOGY 61 ( 136 ) 2167 - 2172 2014.11

Language：English Publisher：H G E UPDATE MEDICAL PUBLISHING S A

Background/Aims: Hepatopancreatoduodenectomy (HPD) is performed to achieve radical resection of malignant biliary tumors. We reviewed clinical outcomes to evaluate the utility of HPD in terms of morbidity and mortality. Methodology: A retrospective analysis was conducted on 17 patients underwent HPD between August 1991 and May 2013; 9 bile duct cancel; 5 advanced gallbladder and 3pancreatic tumor with liver metastasis. Results: The morbidity and mortality rates were 88.3% and 0%, respectively. Univariate analysis showed that a body mass index of >= 22 and preoperative total bilirubin level >= 0.8 mg/dl were significantly associated with severe complications. One, 3- and 5-year survival rate were 73.3%, 60.0% and 30.0%. In 14 patients with biliary carcinoma, univariate analysis showed that a histological grade of G1 was significantly associated with survival. Patients without pancreatic invasion or portal vein invasion tended to survive longer than patients with these types of invasion, although the difference was not significant. Conclusions: HPD can be performed with no mortality and provides a survival benefit for some patients with biliary carcinoma undergoing curative resection. In patients with grade G1 biliary carcinoma without pancreatic or portal vein invasion in particular, this aggressive surgery might offer a chance of long-term survival.

DOI： 10.5754/hge14701

Web of Science

researchmap

　 PREV - NEXT 　

< FUJIWARA Toshiyoshi >

MISC - FUJIWARA Toshiyoshi